Arcadia Biosciences, Inc. (RKDA)

Arcadia Biosciences' stock has been impacted by several events in the past six months. The company announced the exercise of preferred investment options, generating $2.1 million. The termination notice for its proposed business combination with Roosevelt Resources led to a pre-market stock rise. Third Quarter 2025 financial results showed a 26% year-over-year increase in Zola revenues and gross profit margins exceeding 30%. Second Quarter and First Half 2025 financial results showed an 11% year-over-year increase in revenues, driven by Zola's growth. Overall, the company's stock has trended down by 40.86% in the past six months.

Specific detailed information regarding the demand seasonality for Arcadia Biosciences' products and services is not readily available.

Arcadia Biosciences is an agricultural biotechnology company focused on enhancing crop quality and productivity through screening, breeding, and biotechnology. It operates in the Consumer Staples sector, offering products like Zola Coconut Water and Agronomic Wheat Traits under the GoodWheat brand, which includes reduced-gluten and enhanced starch wheat varieties. The company also has a joint venture with Bioceres called Verdeca, focused on HB4 technology in soybeans, and produces plant-based health and wellness products like ProVault and SoulSpring.

Arcadia Biosciences is headquartered in Dallas, Texas, with international operations extending to the United States, Argentina, India, and Canada.

Arcadia Biosciences' brand reputation has been mixed in the past year. The company's stock underperformed both the US Food industry and the broader US Market. The termination of the proposed merger with Roosevelt Resources was met with a positive market reaction. News regarding the growth and expanded distribution of its Zola coconut water product has been positive. Analyst consensus rates Arcadia Biosciences as a "Sell," with some analyses suggesting a "Strong Sell" recommendation. The company's financial health has been in the "Yellow zone" for the last two weeks.

Arcadia Biosciences has 21 institutional owners and shareholders holding 4.77% of the stock, with major holders including Vanguard Group Inc. and Geode Capital Management, Llc. Individual insiders hold 0.817% of the shares, while the general public owns the majority at 94.4%.